Truist analyst Samuel Brodovsky raised the firm’s price target on OrthoPediatrics to $56 from $47 and keeps a Buy rating on the shares as part of a broader research note previewing Q4 earnings in MedTech. The company should be set up to beat and raise through the year while avoiding misses even if external factors continue to impact the business, the analyst tells investors in a research note, adding that investors are also likely to appreciate the conservative approach that the management is taking.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on KIDS:
- OrthoPediatrics Corp. Publishes Environmental, Social, and Governance (“ESG”) Summary Report
- Stifel Predicts a Worrisome 2023 but Recommends These 2 Stocks
- OrthoPediatrics reports preliminary Q4 revenue $31M, consensus $33.8M.
- OrthoPediatrics Corp. Announces Preliminary Unaudited Net Revenue for the Fourth Quarter & Full Year 2022, Provides Financial Outlook for 2023
- OrthoPediatrics establishes direct sales organization in Germany